Cardiovascular revascularization medicine : including molecular interventions
-
Cardiovasc Revasc Med · Jul 2018
Computed tomography (CT) assessment of the membranous septal anatomy prior to transcatheter aortic valve replacement (TAVR) with the balloon-expandable SAPIEN 3 valve.
The lower limit of the membranous septum (MS) is considered an anatomic landmark for the emergence of the Bundle of His into the left ventricle. Computed tomography (CT) assessment of MS anatomy may provide useful information about the risk of conduction abnormalities following transcatheter aortic valve replacement (TAVR). ⋯ The presence of calcium in the device landing zone is associated with increased risk of conduction abnormalities after TAVR with S3. In such cases, a more aortic deployment of the prosthesis may be warranted.
-
Cardiovasc Revasc Med · Apr 2018
Comparative StudySwitch to Ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS).
To investigate platelet reactivity in patients with critical limb ischemia (CLI) after switching from clopidogrel to ticagrelor. ⋯ Among patients with CLI, ticagrelor achieved greater platelet inhibition than clopidogrel during maintenance treatment and at 6h after daily dosing. High on-treatment platelet reactivity to clopidogrel in patients with CLI can be overcome by switching to ticagrelor.
-
Cardiovasc Revasc Med · Apr 2018
Intraprocedural invasive hemodynamic parameters as predictors of short- and long-term outcomes in patients undergoing transcatheter aortic valve replacement.
Evaluation of invasive hemodynamic parameters as prognostic markers of mortality in patients undergoing TAVR. ⋯ In patients with severe aortic stenosis undergoing TAVR, invasive monitoring can assess for hemodynamic prognostic markers of survival.
-
Cardiovasc Revasc Med · Mar 2018
Clinical outcomes of coronary occlusion following transcatheter aortic valve replacement: A systematic review.
Coronary occlusion (CO) is a rare but serious complication following transcatheter aortic valve replacement (TAVR) with limited published data. We sought to evaluate the immediate and short-term outcomes of CO complicating TAVR. ⋯ CO following TAVR is associated with a high procedural and 30-day mortality rate despite aggressive resuscitative measures including percutaneous coronary intervention.